XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaboration and License Agreements - Additional Information (Details) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 16, 2022 USD ($) | Mar. 25, 2021 USD ($) $ / shares | Feb. 14, 2021 USD ($) Program | Feb. 14, 2021 USD ($) | Apr. 29, 2020 USD ($) Unit $ / shares shares | May 31, 2018 USD ($) | Oct. 31, 2017 | Jul. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2020 | Aug. 31, 2019 USD ($) | Sep. 30, 2018 USD ($) Antibodies | Jul. 31, 2018 USD ($) Product | May 31, 2018 USD ($) Program | Oct. 31, 2017 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 shares | Jun. 30, 2020 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | May 27, 2022 USD ($) | Dec. 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,865 |  |  |  |  |  | $ 22,865 |  |  | $ 98,209
Deferred revenue, noncurrent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 54,653 |  |  |  |  |  | 54,653 |  |  | 3,815
Adjustments to profit-sharing amounts |  |  |  |  |  |  |  |  | $ 20,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,253 |  | $ 7,836 |  |  |  | 140,323 | $ 8,988 |  |
Receivable from collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  | 0 |  |  | 773,079
Contract Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39,998 |  | 315 |  |  |  | 52,534 | 169,581 |  |
Collaboration Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 309,145 |  | 102,398 |  |  |  | 1,483,860 | 107,731 |  |
License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,289 |  | 0 |  |  |  | 22,289 | 0 |  |
2020 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustments to profit-sharing amounts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 379,500 |  |  |
GSK | Accrued and Other Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  | 0 |  |  | $ 773,100
2021 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reclassified deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 51,700 |  |  |  |  |  | 51,700 |  |  |
Deferred revenue, noncurrent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 51,700 |  |  |  |  |  | 51,700 |  |  |
2020 Stock Purchase Agreement | 2020 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock (in shares) | shares |  |  |  |  | 6,626,027 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share purchase price per share | $ / shares |  |  |  |  | $ 37.73 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | 2020 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of years conduct certain research and development activities under mutually agreed development plans |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase Decrease In Research And Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,400 |  | 12,000 |  |  |  | $ 24,000 | 49,200 |  |
Maximum percentage of right to perform details in connection with antibody product |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties. |  |  |
Number of units of account | Unit |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration type and program |  |  |  |  |  |  |  |  |  | The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the “Antibody Program”); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the “Vaccine Program”), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the “Functional Genomics Program”). |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development costs |  |  |  |  | 72.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Antibody license transaction price |  |  |  |  | $ 43,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 43,300 |  |  |  |
Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development costs |  |  |  |  | 27.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | 2021 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of separate programs | Program |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment receivable |  |  | $ 225,000 | $ 225,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee to be received |  |  | 300,000 | 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | 2021 GSK | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pre-defined regulatory milestone payment |  |  | $ 200,000 | 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | 2020 GSK | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair market value of the common stock issued |  |  |  |  | $ 206,700 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock price per share | $ / shares |  |  |  |  | $ 36.70 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium received on sale price of common stock |  |  |  |  | $ 43,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2021 Stock Purchase Agreement | 2021 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,924,927 |  |  |  |  |
Issuance of common stock |  |  |  | $ 120,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | 2021 GSK | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair market value of the common stock issued |  | $ 85,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock price per share | $ / shares |  | $ 52.70 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium received on sale price of common stock |  | $ 34,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2021 GSK Collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of years conduct certain research and development activities under mutually agreed development plans |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of share development costs |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of share Profit and loss |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2021 GSK Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase Decrease In Research And Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 300 |  | 400 |  |  |  | $ 1,300 | 1,300 |  |
Fixed consideration |  |  |  | $ 225,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium paid on sale price of common stock |  |  | $ 34,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration |  |  |  | $ 259,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2021 GSK Agreement | Contract Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 168,300 |  |  |  |  |  |
2021 GSK Agreement | GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
contract revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39,800 |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39,800 |  |  |  |  |  | 39,800 |  |  |
Brii Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase Decrease In Research And Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  | 1,300 | 400 |  |
Termination description |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days’ written notice (if the terminating party has not exercised an option for such program) or 180 days' notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party’s uncured material breach on 60 days’ written notice (or 30 days’ notice following failure to make payment). |  |  |  |  |  |  |  |  |  |  |
Written notice to terminate licensed program if not exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |
Written notice to terminate licensed program if exercise |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 180 days |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for failure to make payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Development Programs Exercised by Vir |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee, high end of the range |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  |  |  |
Option exercise fee, low end of the range |  |  |  |  |  | low tens of millions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment on licensed product, high end of the range |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment on licensed product, low end of the range |  |  |  |  |  |  |  |  |  |  |  |  |  |  | low tens of millions |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Development Programs Exercised by Vir | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum sale milestone payment to pay |  |  |  |  |  | 175,000 |  |  |  |  |  |  |  |  | $ 175,000 |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Development Programs Exercised by Brii |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee, high end of the range |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |
Option exercise fee, low end of the range |  |  |  |  |  |  |  |  |  |  |  |  |  |  | mid-single-digit millions |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment on licensed product, high end of the range |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment on licensed product, low end of the range |  |  |  |  |  |  |  |  |  |  |  |  |  |  | mid-single-digit millions |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate sales milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 175,000 |  |  |  |  |  |  |  |  |  |  |
Range of royalty payment to be received |  |  |  |  |  |  |  |  |  | high-teens to high-twenties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Range of royalty payment to be paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  | mid-teens to the high-twenties |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment to be received |  |  |  |  |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Development Programs Exercised by Brii | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum sales milestone to pay |  |  |  |  |  |  |  |  |  | 175,000 |  |  |  |  |  |  |  |  |  |  |  | $ 175,000 |  |  |  |
Brii Agreement | Brii Bio Parent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of development program granted from Vir to Brii | Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |
Maximum number of development program granted from Brii to Vir | Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |
Percentage of ordinary share equal to outstanding share |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9.90% |  |  |  |  |  |  |  |  |  |  |
Carrying value of investment at cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,700 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | $ 2,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options Transaction Price |  |  |  |  |  |  |  | 22,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio Parent | License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from related parties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,300 |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio Parent | VIR-2218 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee received |  |  |  |  |  |  |  | 20,000 |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, noncurrent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,500 |  |  |  |  |  | 1,500 |  |  |
Royalty payment obligation expiration period after first commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | Development Programs Exercised by Brii |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Range of royalty payments to be received |  |  |  |  |  |  |  | 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee received |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | Development Programs Exercised by Brii | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum Sales Milestone To Be Received |  |  |  |  |  |  |  | $ 175,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Alnylam Agreement | Alnylam Pharmaceuticals Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation expiration period after first commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for failure to make payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |
Expenses incurred under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500 |  | 700 |  |  |  | 800 | 2,400 |  |
Written notice period for termination of licensed program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |
Written Notice period to terminate licensed program if under challenge |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 190,000 |  |  |  |  |  |  |  |  |  |
Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115,000 |  |  |  |  |  |  |  |  |  |
Maximum sales milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |
Range of tiered royalties to pay on net sales of products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | high single-digits to the sub-teen double-digits |  |  |  |  |  |  |  |  |  |
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate sales milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |
Range of tiered royalties to pay on net sales of products |  |  |  |  |  |  | The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets |  |  |  |  |  |  |  |  | low double-digits to mid-teens |  |  |  |  |  |  |  |  |  |
Rockefeller Agreement | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination description |  |  |  |  |  |  |  |  |  |  |  |  |  | The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days’ written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days’ written notice for the Company’s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company’s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement. |  |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate agreement by company |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate agreement by counterparty |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |
Royalty obligation period from date of first commercial sale |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense under license agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,700 |  |
Rockefeller Agreement | Rockefeller | Commercialization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual License Maintenance Fees |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |
Rockefeller Agreement | Rockefeller | First Infectious Disease Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payment for achievement of specified milestones |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,300 |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of products covered against milestone payment | Product |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |
MedImmune Agreement | Influenza A and Influenza B |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties payment range on net sales of licensed product |  |  |  |  |  |  |  |  |  |  |  |  | mid-single-digits to sub-teen double-digits |  |  |  |  |  |  |  |  |  |  |  |  |
MedImmune Agreement | MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibodies to develop | Antibodies |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
MedImmune Agreement | MedImmune | Influenza A and Influenza B |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination description |  |  |  |  |  |  |  |  |  |  |  |  | The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days’ notice. Either party may terminate the MedImmune Agreement for cause for the other party’s uncured material breach on 60 days’ notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days’ written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement. |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payment for achievement of specified milestones |  |  |  |  |  |  |  |  |  |  |  |  | $ 331,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of licensed program |  |  |  |  |  |  |  |  |  |  |  |  | 120 days |  |  |  |  |  |  |  |  |  |  |  |  |
Written Notice period to terminate licensed program if under challenge |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties payment range on net sales of licensed product |  |  |  |  |  |  |  |  |  |  |  | low- to mid-single-digits |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate development and regulatory milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 17,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate commercial sales milestone payments |  |  |  |  |  |  |  |  |  |  |  | 60,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  |  |  |  |  |  |  | 155,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 77,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |
2019 and 2020 Xencor Agreement | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination description |  |  |  |  |  |  |  |  |  |  | The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days’ written notice. Either party may terminate each agreement for the other party’s uncured material breach upon 60 days’ written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days’ written notice if any of the Company’s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for uncured material breach |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period to terminate licensed program for failure to make payment |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of licensed program |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written Notice period to terminate licensed program if under challenge |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2020 Xencor Agreement | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties Based on Net Sales of Licensed Products |  |  |  |  |  |  |  |  |  |  | mid-single-digits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties payment expiration period |  |  |  |  |  |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,800 |  | $ 6,300 |  |  |  | $ 109,700 | $ 7,200 |  |
Amendment Number One | 2020 GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,000 |  |  |  |  |  |  |  |
Upfront payment receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,000 |
Termination Agreement | WuXi Biologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront Payment | $ 7,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 + Details
Name: | us-gaap_CostOfRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 25 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598 + Details
Name: | us-gaap_DeferredIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(h)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 + Details
Name: | us-gaap_Investments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.1(c)) -URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(C)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_RevenueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Adjustments To Profit Sharing Amounts + References No definition available. + Details
Name: | vir_AdjustmentsToProfitSharingAmounts
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License maintenance fees required to pay annually. + References No definition available. + Details
Name: | vir_AnnualLicenseMaintenanceFees
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Transaction price for the Antibody License under the collaboration agreement + References No definition available. + Details
Name: | vir_AntibodyLicenseTransactionPrice
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement, number of separate programs agreed to collaborate. + References No definition available. + Details
Name: | vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement, number of units of account. + References No definition available. + Details
Name: | vir_CollaborationAgreementNumberOfUnitsOfAccount
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Costs and expenses for the period incurred under the collaboration agreements. + References No definition available. + Details
Name: | vir_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement termination description. + References No definition available. + Details
Name: | vir_CollaborationAgreementTerminationDescription
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement transaction price consideration. + References No definition available. + Details
Name: | vir_CollaborationAgreementTransactionPriceConsideration
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement, transaction price fixed consideration. + References No definition available. + Details
Name: | vir_CollaborationAgreementTransactionPriceFixedConsideration
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Type and Programs + References No definition available. + Details
Name: | vir_CollaborationTypeAndPrograms
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair market value of common stock issued. + References No definition available. + Details
Name: | vir_FairMarketValueOfCommonStockIssued
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase (decrease) in research And development expense. + References No definition available. + Details
Name: | vir_IncreaseDecreaseInResearchAndDevelopmentExpense
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum aggregate commercial sales milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateCommercialSalesMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate development and regulatory milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial. + References No definition available. + Details
Name: | vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate milestone payment for achievement of specified annual net sales + References No definition available. + Details
Name: | vir_MaximumAggregateSalesMilestonePayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate sales milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateSalesMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum milestone payment for achievement of specified development and regulatory. + References No definition available. + Details
Name: | vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum Number of Development Program Granted from Counterparty + References No definition available. + Details
Name: | vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum Number of Development Program Granted to Counterparty + References No definition available. + Details
Name: | vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum number of products covered against milestone payment. + References No definition available. + Details
Name: | vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum percentage of right to perform details in connection with antibody product. + References No definition available. + Details
Name: | vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum Sale Milestone Payment to Pay + References No definition available. + Details
Name: | vir_MaximumSaleMilestonePaymentToPay
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount of proceeds to pay upon achievement of sales milestone + References No definition available. + Details
Name: | vir_MaximumSalesMilestonToPay
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum milestone payment for achievement of specified annual net sales. + References No definition available. + Details
Name: | vir_MaximumSalesMilestonePayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum sales milestone to be received. + References No definition available. + Details
Name: | vir_MaximumSalesMilestoneToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of antibodies to develop. + References No definition available. + Details
Name: | vir_NumberOfAntibodiesToDevelop
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years conduct certain research and development activities under mutually agreed development plans. + References No definition available. + Details
Name: | vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition One time upfront payment. + References No definition available. + Details
Name: | vir_OneTimeUpfrontPayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option exercise fee consideration to be received. + References No definition available. + Details
Name: | vir_OptionExerciseFeeConsiderationToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the high end of the range of option exercise fee upon exercise of a program. + References No definition available. + Details
Name: | vir_OptionExerciseFeeHighEndOfTheRange
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the low end of the range of option exercise fee upon exercise of a program. + References No definition available. + Details
Name: | vir_OptionExerciseFeeLowEndOfTheRange
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option exercise fee received. + References No definition available. + Details
Name: | vir_OptionExerciseFeeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Options transaction price + References No definition available. + Details
Name: | vir_OptionsTransactionPrice
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of development costs. + References No definition available. + Details
Name: | vir_PercentageOfDevelopmentCosts
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of ordinary share equal to outstanding share. + References No definition available. + Details
Name: | vir_PercentageOfOrdinaryShareEqualToOutstandingShare
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of share development costs. + References No definition available. + Details
Name: | vir_PercentageOfShareDevelopmentCosts
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pre-defined regulatory milestone consideration receivable. + References No definition available. + Details
Name: | vir_PreDefinedRegulatoryMilestoneConsiderationReceivable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Premium paid on sale price of common stock. + References No definition available. + Details
Name: | vir_PremiumPaidOnSalePriceOfCommonStock
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Premium received on sale price of common stock. + References No definition available. + Details
Name: | vir_PremiumReceivedOnSalePriceOfCommonStock
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Profits and losses sharing percentage. + References No definition available. + Details
Name: | vir_ProfitsAndLossesSharingPercentage
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Range of royalty payment to be paid by counterparty. + References No definition available. + Details
Name: | vir_RangeOfRoyaltyPaymentToBePaid
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Range of royalty payment to be received by the company upon exercised of the development programs by counterparty. + References No definition available. + Details
Name: | vir_RangeOfRoyaltyPaymentToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Range of royalty payments to be received. + References No definition available. + Details
Name: | vir_RangeOfRoyaltyPaymentsToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Range of tiered royalties to pay on annual net sales of products. + References No definition available. + Details
Name: | vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reclassified deferred revenue. + References No definition available. + Details
Name: | vir_ReclassifiedDeferredRevenue
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestone payment on licensed product, high end of the range. + References No definition available. + Details
Name: | vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestone payment on licensed product, low end of the range. + References No definition available. + Details
Name: | vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty. + References No definition available. + Details
Name: | vir_RegulatoryMilestonePaymentToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development expense under license agreement + References No definition available. + Details
Name: | vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties payment based on net sales of licensed products. + References No definition available. + Details
Name: | vir_RoyaltiesBasedOnNetSalesOfLicensedProducts
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years that royalties payment expired. + References No definition available. + Details
Name: | vir_RoyaltiesPaymentExpirationPeriod
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalties payment range on net sales of licensed product. + References No definition available. + Details
Name: | vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty obligation period from date of first commercial sale. + References No definition available. + Details
Name: | vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payment obligation expiration period after first commercial sales. + References No definition available. + Details
Name: | vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment receivable. + References No definition available. + Details
Name: | vir_UpfrontPaymentReceivable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Written notice period for termination of licensed program. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForTerminationOfLicensedProgram
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminate agreement by company. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodToTerminateAgreementByCompany
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminate agreement by counterparty. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodToTerminateAgreementByCounterparty
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminate licensed program for failure to make payment. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminate licensed program for uncured material breach. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice to terminate licensed program following the exercise of an option for such program. + References No definition available. + Details
Name: | vir_WrittenNoticeToTerminateLicensedProgramIfExercise
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice to terminate licensed program if not exercise. + References No definition available. + Details
Name: | vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vir_ContractRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_CollaborationRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AntibodyProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_VaccineProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_BriiBioParentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_Vir2218Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstSiRNAProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_RockefellerUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_CommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_XencorIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_AmendmentNumberOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |